Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

PubWeight™: 3.18‹?› | Rank: Top 1%

🔗 View Article (PMID 18759926)

Published in Immunol Rev on August 01, 2008


Brian T Fife1, Jeffrey A Bluestone

Author Affiliations

1: Department of Medicine, UCSF Diabetes Center, University of California, San Francisco, CA 94113, USA.

Articles citing this

(truncated to the top 100)

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20

Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res (2013) 3.27

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 2.95

PD-1 signaling in primary T cells. Immunol Rev (2009) 2.66

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54

The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34

Mesenchymal cells of the intestinal lamina propria. Annu Rev Physiol (2011) 2.18

PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol (2009) 2.14

Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00

An effective approach to prevent immune rejection of human ESC-derived allografts. Cell Stem Cell (2014) 1.73

PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care (2010) 1.73

CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci U S A (2009) 1.52

Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A (2017) 1.43

What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 1.42

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol (2016) 1.39

Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer (2013) 1.34

Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset. J Immunol (2010) 1.31

Endogenous retinoids in the pathogenesis of alopecia areata. J Invest Dermatol (2012) 1.28

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med (2011) 1.23

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep (2015) 1.18

The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia (2014) 1.18

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. Front Immunol (2014) 1.18

CD69 association with Jak3/Stat5 proteins regulates Th17 cell differentiation. Mol Cell Biol (2010) 1.17

Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther (2012) 1.15

How might infant and paediatric immune responses influence malaria vaccine efficacy? Parasite Immunol (2009) 1.11

Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood (2010) 1.07

Re-establishing immunological self-tolerance in autoimmune disease. Nat Med (2012) 1.06

Culling of activated CD4 T cells during typhoid is driven by Salmonella virulence genes. J Immunol (2009) 1.04

Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol (2014) 1.04

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget (2015) 1.02

Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol (2013) 1.02

Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01

Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J Exp Med (2015) 1.01

Intracellular events and cell fate in filovirus infection. Viruses (2011) 1.01

Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med (2012) 1.00

Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res (2012) 0.98

Immunoregulatory molecules are master regulators of inflammation during the immune response. FEBS Lett (2012) 0.98

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest (2015) 0.98

Tumor antigen cross-presentation and the dendritic cell: where it all begins? Clin Dev Immunol (2010) 0.97

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol (2013) 0.96

The role of coinhibitory signaling pathways in transplantation and tolerance. Front Immunol (2012) 0.95

Regulatory T cells and their roles in immune dysregulation and allergy. Immunol Res (2014) 0.94

Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells. J Immunol (2012) 0.94

Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. Bone Marrow Transplant (2016) 0.94

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget (2016) 0.93

Chronic infection drives expression of the inhibitory receptor CD200R, and its ligand CD200, by mouse and human CD4 T cells. PLoS One (2012) 0.93

B7 family molecules as regulators of the maternal immune system in pregnancy. Am J Reprod Immunol (2010) 0.93

The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes. J Immunol (2013) 0.93

Relative efficiency of porcine and human cytotoxic T-lymphocyte antigen 4 immunoglobulin in inhibiting human CD4+ T-cell responses co-stimulated by porcine and human B7 molecules. Immunology (2011) 0.92

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother (2014) 0.92

Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol (2012) 0.91

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol (2017) 0.91

Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitro. Vet Res (2013) 0.91

Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer. Front Microbiol (2011) 0.91

Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proc Natl Acad Sci U S A (2014) 0.90

Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS One (2013) 0.90

Ligation of cytotoxic T lymphocyte antigen-4 to T cell receptor inhibits T cell activation and directs differentiation into Foxp3+ regulatory T cells. J Biol Chem (2012) 0.89

Immunogenetics of autoimmune thyroid diseases: A comprehensive review. J Autoimmun (2015) 0.89

A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. Front Immunol (2016) 0.88

Coinhibitory molecules in autoimmune diseases. Clin Dev Immunol (2012) 0.88

Low levels of NF-κB/p65 mark anergic CD4+ T cells and correlate with disease severity in sarcoidosis. Clin Vaccine Immunol (2010) 0.88

Taming tissue-specific T cells: CTLA-4 reins in self-reactive T cells. Nat Immunol (2010) 0.88

B7-H1 (programmed cell death ligand 1) is required for the development of multifunctional Th1 cells and immunity to primary, but not secondary, Salmonella infection. J Immunol (2010) 0.87

Autoimmune thyroiditis: a model uniquely suited to probe regulatory T cell function. J Autoimmun (2009) 0.87

Induction and stability of the anergic phenotype in T cells. Semin Immunol (2013) 0.87

Challenges to the clinical application of pluripotent stem cells: towards genomic and functional stability. Genome Med (2012) 0.86

Activation-induced accumulation of B and T lymphocyte attenuator at the immunological synapse in CD4+ T cells. J Leukoc Biol (2009) 0.86

Targeting Treg signaling for the treatment of autoimmune diseases. Curr Opin Immunol (2015) 0.85

Differential capacity of human skin dendritic cells to polarize CD4+ T cells into IL-17, IL-21 and IL-22 producing cells. PLoS One (2012) 0.85

Tumor-associated antigen expressing Listeria monocytogenes induces effective primary and memory T-cell responses against hepatic colorectal cancer metastases. Ann Surg Oncol (2011) 0.85

PD-1 signalling in CD4(+) T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance. Immunology (2010) 0.85

Graves' ophthalmopathy: a review of immunogenetics. Curr Genomics (2011) 0.84

Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation. Drug Des Devel Ther (2010) 0.84

Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. J Immunol (2015) 0.83

Comparison of biomarkers for systemic juvenile idiopathic arthritis. Pediatr Res (2015) 0.83

Induction of Multiple Immune Regulatory Pathways with Differential Impact in HCV/HIV Coinfection. Front Immunol (2014) 0.82

Aberrant expression of costimulatory molecules in splenocytes of the mevalonate kinase-deficient mouse model of human hyper-IgD syndrome (HIDS). J Inherit Metab Dis (2011) 0.82

The expression of programmed death-1 in circulating CD4+ and CD8+ T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics. Gut Liver (2013) 0.82

PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis. Am J Surg Pathol (2010) 0.82

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat Commun (2016) 0.81

The current status of checkpoint inhibitors in metastatic bladder cancer. Clin Exp Metastasis (2016) 0.81

Tolerance Induction in Liver. Int J Organ Transplant Med (2015) 0.81

Nuclear export of histone deacetylase 7 during thymic selection is required for immune self-tolerance. EMBO J (2012) 0.81

Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol (2015) 0.81

The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract (2016) 0.81

PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. Pharmacotherapy (2016) 0.81

Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol (2016) 0.80

Association of programmed death-1 gene polymorphism rs2227981 with tumor: evidence from a meta analysis. Int J Clin Exp Med (2015) 0.80

Immune interventions to preserve β cell function in type 1 diabetes. J Investig Med (2016) 0.80

The Foxo and the hound: chasing the in vivo regulation of T cell populations during infection. Nat Immunol (2009) 0.80

Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade. J Immunol (2015) 0.80

Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother (2011) 0.80

Nardilysin-dependent proteolysis of cell-associated VTCN1 (B7-H4) marks type 1 diabetes development. Diabetes (2014) 0.80

PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer. Mol Clin Oncol (2014) 0.80

T-cell tolerance in cancer. Immunotherapy (2013) 0.79

HLA-DQB1* alleles and genetic susceptibility to type 1 diabetes mellitus. World J Diabetes (2012) 0.79

Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). Ther Adv Hematol (2016) 0.79

Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism. Cell Immunol (2009) 0.79

The immune system in Duchenne muscular dystrophy: Friend or foe. Rare Dis (2015) 0.78

Articles by these authors

(truncated to the top 100)

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33

Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature (2008) 12.45

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84

Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00

Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44

The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71

The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20

Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature (2007) 4.94

Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 4.68

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes (2005) 4.19

Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03

Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86

Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med (2005) 3.70

Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 3.40

Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 3.18

A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 3.07

CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04

Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol (2009) 2.93

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86

NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity (2004) 2.80

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68

Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 2.57

Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant (2004) 2.55

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54

Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52

Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity (2013) 2.41

Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30

Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 2.13

Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev (2006) 2.13

CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med (2008) 2.07

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02

Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest (2003) 1.95

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 1.90

Cell-based therapeutics: the next pillar of medicine. Sci Transl Med (2013) 1.83

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes (2013) 1.79

Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol (2006) 1.75

How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74

Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest (2004) 1.74

Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol (2005) 1.73

Murine pancreatic islet isolation. J Vis Exp (2007) 1.68

Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes (2007) 1.67

Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol (2005) 1.67

A resource for the conditional ablation of microRNAs in the mouse. Cell Rep (2012) 1.66

Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65

Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest (2010) 1.63

Notch 1 signaling regulates peripheral T cell activation. Immunity (2004) 1.61

Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol (2006) 1.55

IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 1.54

The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol (2013) 1.50

Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49

Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol (2011) 1.49

CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol (2011) 1.45

Production of α-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol (2013) 1.42

Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One (2011) 1.39

Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol (2005) 1.38

Immune therapy and β-cell death in type 1 diabetes. Diabetes (2013) 1.33

Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med (2013) 1.29

Transplantation of pancreatic islets into the kidney capsule of diabetic mice. J Vis Exp (2007) 1.28

Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol (2002) 1.28

Regulatory T cells: stability revisited. Trends Immunol (2011) 1.27

The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med (2011) 1.26

Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26

When ligand becomes receptor--tolerance via B7 signaling on DCs. Nat Immunol (2002) 1.25

Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol (2011) 1.25

Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol (2003) 1.25

CTLA-4 and tolerance: the biochemical point of view. Immunol Res (2003) 1.24

Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol (2013) 1.24

The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol (2002) 1.24

Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation (2010) 1.23

Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2003) 1.20

T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol (2009) 1.16

Inability to induce tolerance through direct antigen presentation. Am J Transplant (2002) 1.16

Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol (2008) 1.14

MicroRNA regulation of T-cell differentiation and function. Immunol Rev (2013) 1.13

The immune tolerance network: a new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol (2002) 1.13

Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. J Immunol (2011) 1.12

Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol (2007) 1.11

Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes (2010) 1.10

MicroRNA 10a marks regulatory T cells. PLoS One (2012) 1.09

Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol (2005) 1.09

CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nat Immunol (2003) 1.06

Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest (2006) 1.05

microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol (2013) 1.05

B7-independent inhibition of T cells by CTLA-4. J Immunol (2005) 1.05

Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J Immunol (2005) 1.04

Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One (2010) 1.03

Mechanisms of tolerance. Immunol Rev (2011) 1.01

Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease. Eur J Immunol (2007) 1.00

B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest (2007) 1.00

The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found Symp (2003) 1.00